TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07505771: A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer

Sponsor: Immunome, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 105 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07505771 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07505771 Rescue Dossier →